Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812Phase 2Terminated
- Sponsor
- Ichnos Sciences Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of ISB 1442 in multiple myeloma (MM) (2 arms), sponsored by Ichnos Sciences Inc. Primary endpoints: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs) at 18 months, Number of Dose-Limiting Toxicities (DLTs) at 28 days and 1 more. Started Sep 2022; status: terminated.
02
Drugs
ISB 1442
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05427812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427812.